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Abstract
Background
Observational studies of a putative association between hormonal contraception (HC) and
HIV acquisition have produced conflicting results. We conducted an individual participant
data (IPD) meta-analysis of studies from sub-Saharan Africa to compare the incidence of
HIV infection in women using combined oral contraceptives (COCs) or the injectable pro-
gestins depot-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-
EN) with women not using HC.
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Methods and Findings
Eligible studies measured HC exposure and incident HIV infection prospectively using stan-
dardized measures, enrolled women aged 15–49 y, recorded15 incident HIV infections,
and measured prespecified covariates. Our primary analysis estimated the adjusted hazard
ratio (aHR) using two-stage random effects meta-analysis, controlling for region, marital sta-
tus, age, number of sex partners, and condom use. We included 18 studies, including
37,124 women (43,613 woman-years) and 1,830 incident HIV infections. Relative to no HC
use, the aHR for HIV acquisition was 1.50 (95% CI 1.24–1.83) for DMPA use, 1.24 (95% CI
0.84–1.82) for NET-EN use, and 1.03 (95% CI 0.88–1.20) for COC use. Between-study het-
erogeneity was mild (I2< 50%). DMPA use was associated with increased HIV acquisition
compared with COC use (aHR 1.43, 95% CI 1.23–1.67) and NET-EN use (aHR 1.32, 95%
CI 1.08–1.61). Effect estimates were attenuated for studies at lower risk of methodological
bias (compared with no HC use, aHR for DMPA use 1.22, 95% CI 0.99–1.50; for NET-EN
use 0.67, 95% CI 0.47–0.96; and for COC use 0.91, 95% CI 0.73–1.41) compared to those
at higher risk of bias (pinteraction = 0.003). Neither age nor herpes simplex virus type 2 infec-
tion status modified the HC–HIV relationship.
Conclusions
This IPD meta-analysis found no evidence that COC or NET-EN use increases women’s
risk of HIV but adds to the evidence that DMPA may increase HIV risk, underscoring the
need for additional safe and effective contraceptive options for women at high HIV risk. A
randomized controlled trial would provide more definitive evidence about the effects of hor-
monal contraception, particularly DMPA, on HIV risk.
Introduction
There is ongoing debate whether hormonal contraception (HC) increases the risk of HIV ac-
quisition [1–4]. Strong evidence for an association would have important implications for sex-
ual and reproductive health, particularly in areas of sub-Saharan Africa where the incidence of
both HIV infection and unintended pregnancy remain high [5–7]. Contraception has profound
benefits for women and societies, including reduced maternal and infant mortality and mor-
bidity, empowerment of women to make choices about fertility, associated economic improve-
ment, and a reduction in the number of babies born with HIV [8]. Although contraceptive
prevalence remains low in much of sub-Saharan Africa, combined oral contraceptives (COCs,
containing both estrogen and progestin) and the injectable progestins depot-medroxyproges-
terone acetate (DMPA, given every 3 mo) and norethisterone enanthate (NET-EN, given every
2 mo) are the most popular contraceptive methods [9], with DMPA being the most commonly
used method overall.
HC, particularly DMPA, has been reported to be associated with increased risk of HIV ac-
quisition in some, but not all, studies [1–4]. Such a relationship is biologically plausible based
on laboratory, animal, and human data [1, 10]. However, many individual studies have impor-
tant methodological flaws, including lack of accurate measurement of hormonal contraceptive
exposures, failure to control for important confounding factors, poor follow-up, and small
sample sizes [2, 3]. A systematic review of studies published up to December 2011 [3] and
AMeta-analysis of Hormonal Contraception and Risk of HIV Acquisition
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updated to January 15, 2014 [4], did not reach definitive conclusions about the potential risk of
HIV acquisition associated with injectable progestins; the authors did not perform a meta-anal-
ysis because of concern about between-study heterogeneity, although this was not quantified
statistically [3, 4]. A linked technical meeting of the World Health Organization in 2012 re-
quested additional high-quality research to help better inform policy-makers, clinicians, and
women about this important reproductive health issue [11].
Examining individual participant data (IPD) from several different studies can overcome
some of the methodological limitations of reviews of aggregated data [12]. Our goal was to
assess the risk of HIV acquisition associated with different hormonal contraceptives by com-
bining data from large prospective longitudinal studies in an IPD meta-analysis. The
specific objectives of this study were (1) to determine whether a woman’s hormonal contracep-
tive method increases the risk of HIV acquisition compared to women not using HC, (2) to
evaluate whether age or herpes simplex virus type 2 (HSV-2) infection status modifies any
effect of HC on the risk of HIV acquisition, and (3) to directly compare the risks of
HIV acquisition between three groups of hormonal contraceptive (COC, DMPA, and
NET-EN) users.
Methods
The Protection of Human Subjects Committee of FHI 360 approved the study and judged it as
exempt research (PHSC #10263). All included studies had relevant country-specific institution-
al ethical review and regulatory board approvals, and all participants within each study provid-
ed written informed consent for study participation.
The IPD meta-analysis followed a protocol (S1 Text) and a prespecified analysis plan (S2
Text). We report our findings in accordance with the Preferred Items of Reporting for System-
atic Reviews and Meta-Analyses (PRISMA) (S1 Checklist) [13] and a checklist of items specific
to IPD meta-analyses (S2 Checklist) [14].
Study Eligibility and Inclusion Criteria
Cohort studies that prospectively collected data on both hormonal contraceptive use
(COC, DMPA, or NET-EN) and incident HIV-1 infections in women aged 15 to 49 y from
sub-Saharan Africa were eligible. We considered randomized controlled trials (RCTs) of HIV
prevention interventions as cohort studies because HIV incidence is the outcome and many of
these trials collected detailed longitudinal contraception data; several groups have published
such secondary analyses of RCT data [15–20]. We excluded studies with<15 incident HIV in-
fections,>5% missing HIV infection or HC data, or scheduled follow-up visits>6 mo apart.
Information Sources
We used three sources of information. First, we used a database containing IPD from ten stud-
ies that contributed to an IPD meta-analysis of the effects of vaginal practices on the risk of
HIV acquisition among women [21], amassed by the Vaginal Practices Research Partnership
(VPRP). Second, we sought additional well-documented datasets from prospective cohort
studies and RCTs completed by September 30, 2012, by asking collaborators and investigators
of HIV prevention trials. Third, we checked the bibliographies of the two published systematic
reviews for studies published up to December 2011 [1, 3]. We also checked the bibliography to
January 15, 2014, of an updated version of one of the reviews [4].
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Study Selection
The ten studies contributing to the VPRP IPD meta-analysis [21] all had prospective hormonal
contraceptive use data and met all other inclusion criteria. We reviewed the full text of all other
identified publications and applied our inclusion and exclusion criteria. For eligible studies in-
volving oral or vaginal microbicides that contained antiretroviral drugs, only data from the
non-antiretroviral control arm were included (Table 1).
Data Collection, Data Management, and Data Items
Two investigators (C.S.M. and P.C.) contacted the investigators of eligible component studies
by email or phone to ask their permission to use their study data in the meta-analysis. We col-
lected information for the individual studies included in this analysis from protocols, question-
naires, and publications, and asked study investigators to determine whether desired variables
had been collected or could be derived. We used the existing structure of the VPRP database to
include the data from additional studies, which included three levels of variables: study, indi-
vidual, and visit level. Study-level variables consisted of country, study site, study design and
population group(s), study aims, recruitment period, study duration, frequency of follow-up
visits, planned follow-up duration for each woman, definitions of primary and secondary study
outcomes, and diagnostic procedures. Individual-level variables included age, education, em-
ployment status, religion, socio-economic indicators, parity, and marital status. Visit-level vari-
ables were hormonal contraceptive use, pregnancy status, vaginal practices, numbers and type
of sexual partners, coital frequency, transactional sex, condom use, sexual partner risk, and
HIV, HSV-2, and other diagnosed sexually transmitted or reproductive tract infections. We in-
cluded individual- and visit-level items for all study participants who had follow-up HIV and
HC data. We excluded data from studies with scheduled follow-up visits>6 mo apart.
Three statisticians and data managers (P.C., C.K., and A. Bernholc) at the study coordinat-
ing center (FHI 360) worked closely with data managers and investigators of the individual
studies to clarify issues about variable definition and missing, incomplete, or implausible data.
Of the 18 included studies, datasets for 13 were provided either by their own data manager or
through the VPRP. Investigators of the other five studies sent raw data to the coordinating cen-
ter staff, who provided data management support.
Primary Outcome and Exposure Measures
The primary outcome was incident HIV infection, defined as a new HIV infection following a
preceding visit where the participant was confirmed HIV negative. The criteria for HIV diag-
nosis were defined by the investigators of the individual studies and were typically based on a
positive ELISA/rapid test confirmed by a positive Western blot or HIV PCR test. The midpoint
between the last negative and first positive HIV test was used as the estimated HIV
infection date.
The primary exposure was hormonal contraceptive use with COCs (any preparation includ-
ing estrogen plus progestin), DMPA (150 mg intramuscularly every 3 mo), or NET-EN (200
mg intramuscularly every 2 mo). COC, DMPA, and NET-EN use were recorded at each study
visit. Studies that did not specify the type of injectable hormone were categorized as DMPA in
the primary analysis because only South Africa had a significant number of NET-EN users. We
examined in a sensitivity analysis the effect of limiting the meta-analysis to only studies where
the injectable was specified. The comparison group was women not using hormonal contracep-
tives. This group included sterilized women, women using condoms (consistently or inconsis-
tently), women using non-hormonal intrauterine devices or diaphragms, and women not using
any modern contraceptive method.
AMeta-analysis of Hormonal Contraception and Risk of HIV Acquisition
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Study participants were censored at the time they reported using a hormonal method not in-
cluded in the study (such as the progestin-only pill or hormonal implants), at the end of the
study, or at their last follow-up visit.
Assessment of Study Methods and the Risk of Bias
We developed a list of methodological features of the component studies that could bias the es-
timates of the association between HC and HIV acquisition or affect their precision. We used
criteria for items specific to the research question [3, 4, 22]. Additional criteria for cohort stud-
ies were drawn from the Newcastle-Ottawa Scale [23], the Downs and Black instrument [24],
the Strengthening the Reporting of Observational Studies in Epidemiology Statement [25], and
the Meta-Analysis of Observational Studies in Epidemiology checklist [26].
For each study we assessed documentation about the following items to classify the study as
being at either lower or higher risk of bias: participant retention rate [3, 4, 22–27] (<80% ver-
sus80%); measurement of important confounders (pregnancy, coital frequency, marital sta-
tus/living with partner, and transactional sex [yes versus no]); measurement of contraceptive
method use (every 3 mo or more frequently versus less frequently); and percentage of partici-
pants in a non-hormonal-contraceptive comparison group at baseline (10% versus>10%).
Two investigators (C.S.M. and N.L.) independently evaluated each study and reached agree-
ment about any differences through discussion. Studies for which all items were at lower risk of
bias were categorized as “lower risk of bias,” and all other studies were categorized as “higher
risk of bias,” for evaluating the association between HC and HIV.
Statistical Analysis
We used Cox proportional hazards models with time-varying covariates to examine the associ-
ation in each study between time-varying exposure to each hormonal contraceptive (COC,
DMPA, and NET-EN) and HIV acquisition, and expressed the comparison with no hormonal
contraceptive use as hazard ratios (HRs) with 95% confidence intervals. Follow-up time was
censored at the first of the following: estimated date of HIV infection, the last follow-up visit,
the end of the study, or after 30 mo of follow-up (owing to sparse data). The primary analysis
used a two-stage approach to IPD meta-analysis; we used the effect estimate from each individ-
ual study and combined the effect estimates using random effects meta-analysis to estimate a
summary HR (with 95% CI). We used the I2 statistic to evaluate between-study heterogeneity
(ranging from 0% to 100%) in this model and considered I2 values below 50% as indicating
mild to moderate heterogeneity [12, 28]. We examined the consistency of the results from the
two-stage random effects model with those from a two-stage fixed effects model and with those
from one-stage Cox regression analyses in which data were combined across all studies using
study as the strata [28, 29]. No missing data were imputed in analyses; follow-up visits with a
missing covariate did not contribute to the multivariable analyses. All statistical analyses were
conducted using SAS (version 9.3, SAS Institute, Cary, North Carolina, US).
We constructed two multivariable models for each study: the primary analysis included a
common set of covariates for each study (prespecified covariates were age, marital status/living
with partner, condom use, and number of sex partners; region of study was added later to this
group); the second model included specific covariates for each individual study that showed
statistical evidence of confounding. We examined statistical evidence of confounding of the as-
sociation between each hormonal contraceptive exposure and HIV infection in the individual
studies. Each potential confounding factor was added to a model that included hormonal con-
traceptive exposure and the prespecified covariates. If addition of the variable resulted in the
HR changing by10% for any of the hormonal contraceptive exposures, we included the
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covariate in the multivariable model. Variables evaluated for confounding included region of
study, recent sexual behavior (concurrent sex partners, coital frequency, transactional sex, anal
sex, oral sex), vaginal practices, reproductive health factors (parity, pregnancy history and sta-
tus, lactation status), physical exam variables (cervical ectopy, genital epithelial findings), pres-
ence of cervical infections (Chlamydia trachomatis, Neisseria gonorrhoeae), and presence of
vaginal infections (bacterial vaginosis, Trichomonas vaginalis, vulvovaginal candidiasis).
We examined statistical evidence for effect modification using likelihood ratio tests. If the p-
value was<0.05, we present the stratified results. Prespecified study objectives were to deter-
mine whether associations between use of each hormonal contraceptive method (COC,
DMPA, and NET-EN) and HIV acquisition differed among young women (15–24 y) and older
women (25–49 y) and whether HSV-2 infection status altered the effect of HC on the risk of
HIV acquisition [30, 31]. We conducted the following prespecified subgroup analyses: risk of
methodological bias in component studies (higher risk versus lower risk of bias), region of
study (southern Africa versus South Africa versus east Africa), and underlying HIV incidence
(higher versus lower in the non-hormonal-contraceptive comparison group for each study).
We also did prespecified sensitivity analyses to examine hormonal contraceptive method
switching (censoring at last visit before switching), limiting the analyses to only studies where
the type of injectable was specified, accounting for pregnancy status (two methods: excluding
all women who became pregnant during the study and censoring women at the last visit prior
to pregnancy), and limiting person-time to periods with no condom use (by including only
person-time from women never reporting condom use and person-time up to the time in a
study that a woman first reported condom use). In post hoc subgroup analyses we examined
whether engaging in transactional sex modified the relationship between HC and HIV infec-
tion and examined results separately for cohort studies and RCTs. We also explored whether
our findings would differ if we added the results of eligible studies for which we could not ob-
tain individual-level data.
Results
We included the ten studies [15, 16, 20, 30, 32–42] (Table 1) that contributed to the VPRP
meta-analysis [21]. Our search strategy identified 19 additional potentially eligible studies
(Fig. 1) [6, 43–59]. We excluded 11 of these studies: two were not conducted in sub-Saharan
Africa [51, 56], and six did not meet the other inclusion criteria because they had>5% missing
exposure data [54], follow-up visits>6 mo apart [52, 53, 55], or no longitudinal data (from vis-
its6 mo apart) on injectable contraception [5, 50]. For two studies we did not reach an agree-
ment with the study investigators to use their datasets by our cutoff date of September 2012
[47, 58]; we could not make contact with the responsible investigator of one study despite re-
peated attempts [45]. Additional searches after September 2012 identified one additional pub-
lished study that did not meet the inclusion criteria [60] and two conference abstracts from
studies that fulfilled the inclusion criteria [61, 62] (Table 2).
Description of Studies and Study Populations
Overall, there were nine cohort studies [30, 32, 34, 35, 37, 38, 48, 49, 57] and nine RCTs [5, 6,
15, 16, 17, 33, 36, 43, 44] (Table 1; S1 Table). The 18 studies were conducted in nine countries.
Of the 37,124 participants, 27% were from east Africa (Kenya, Uganda, Tanzania, Rwanda),
55% were from South Africa, and 18% were from other southern African countries (Zambia,
Zimbabwe, Malawi, Botswana). Participants were sexually active women recruited from com-
munity settings, reproductive health or family planning clinics, or bars and other recreational
facilities where high levels of HIV infection have been documented (Table 1). Most studies
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followed women for 12 to 24 mo with clinic visits monthly, quarterly, or every 6 mo. Retention
at 12 mo ranged from 39% to 99%. Studies documented from 17 [49] to 413 [44] incident HIV
infections, with infection rates ranging from 2.1 [15] to 15.2 [38] per 100 woman-years; most
studies recorded incidence rates between 2.5 and 5.0 per 100 woman-years.
Five of the 18 included studies were judged to be at lower risk of bias for the analysis of HC
and HIV acquisition [17, 18, 20, 30, 48] (Table 3). Amongst the other 13 studies, eight had
<80% retention at 12 mo, eight did not include a minimal set of confounders judged to be im-
portant, one did not measure HC every 3 mo or more often, and two had<10% of study partic-
ipants in a no-HC comparison group.
Fig 1. Flow diagram of studies included in individual participant data meta-analysis of hormonal contraception and HIV acquisition.
doi:10.1371/journal.pmed.1001778.g001
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Contraceptive Use
At baseline about half of the women (18,216/36,973) were not using HC (the comparison
group), 26% (9,722/36,973) were using DMPA, 16% (5,835/36,973) were using COCs, and 9%
(3,200/36,973) were using NET-EN. Although DMPA was used by about a quarter of women
in all three regions, COC use was lower in South Africa (1,721/20,449, 8%) than in other south-
ern African countries (2,578/6,645, 39%). Most NET-EN use was in South Africa, and the high-
est proportion of women not using HC was in east Africa (5,778/9,859, 59%). During follow-
up, 67% (23,628/35,090) of women remained on the same contraceptive method. Eight percent
(1,424/18,464) of women originally using a hormonal contraceptive method switched to
Table 3. Assessment of risk of bias for the 18 studies included in the individual participant data
meta-analysis.
Study Number
and Country/
Region
 80%
Retention
Rate
Measurement of
Important
Confoundersa
Contraceptive Method
Measured Every 3 mo or
More Frequently
 10% in No-HC
Comparison
Group
Lower
Risk of
Biasb
1. Kenya [32, 39] No Yes Yes Yes No
2. South Africa
[15, 41]
No No Noc Yes No
3. Uganda,
Zimbabwe [30,
31]
Yes Yes Yes Yes Yes
4. Kenya [33] No No Yes Yes No
5. Tanzania [34] No Yes Yes Yes No
6. Tanzania [16,
40]
Yes No Yes Yes No
7. Zimbabwe,
South Africa [20,
36]
Yes Yes Yes Yes Yes
8. South Africa
[57]
No No Yes Yes No
9. South Africa
[37]
No No Yes Yes No
10. South Africa
[38]
No No Yes Yes No
11. Malawi,
Zimbabwe [35,
42]
Yes No Yes Yes No
12. South Africa
[18, 43]
Yes Yes Yes Yes Yes
13. Uganda [49] No Yes Yes Yes No
14. Tanzania [48] Yes Yes Yes Yes Yes
15. East/southern
Africa [17, 59]
Yes Yes Yes Yes Yes
16. East/southern
Africa [19, 44]
Yes No Yes Yes No
17. South Africa
[5]
Yes Yes Yes No No
18. East/southern
Africa [6]
Yes Yes Yes No No
aImportant confounders include pregnancy status, coital frequency, marital status/living with partner,
transactional sex; “yes” indicates all measured; “no” indicates one or more missing.
bLower risk of bias based on “yes” to all: 80% followed at 12 mo, measurement of important confounders,
contraceptive method measured every 3 mo or more frequently, and 10% in no-HC comparison group.
cFollow-up visits every 6 mo.
doi:10.1371/journal.pmed.1001778.t003
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another hormonal method, while 14% (2,630/18,464) discontinued HC. Among those not
using HC at baseline, 17% (2,783/16,626) initiated a hormonal method during follow-up. Thir-
teen percent (4,625/35,090) of women overall switched contraceptive methods multiple times.
Contraceptive Use and HIV Acquisition
Across studies there were 1,830 incident HIV infections, for an overall incidence of 4.2 per 100
woman-years. Based on time-varying exposure to contraceptive method, HIV incidence was
highest among DMPA users (5.1 per 100 woman-years), followed by NET-EN users (4.8 per
100 woman-years), the no-HC group (3.9 per 100 woman-years), and COC users (3.4 per 100
woman-years).
In univariable analyses, COC use was not associated with HIV acquisition (HR 1.01, 95% CI
0.84–1.21), while DMPA use (HR 1.56, 95% CI 1.31–1.86) and NET-EN use (HR 1.51, 95% CI
1.21–1.98) were. In multivariable analyses using a two-stage random effects approach and con-
trolling for a common set of covariates for each study (region plus the prespecified covariates
age, marital status/living with partner, number of sex partners, and condom use), we found no
association between COC use and HIV acquisition (adjusted HR [aHR] 1.03, 95% CI 0.88–
1.20) (Table 4; Fig. 2), DMPA was associated with an increased risk of HIV acquisition (aHR
1.50, 95% CI 1.24–1.83), and the association between NET-EN use and HIV acquisition be-
came weaker (aHR 1.24, 95% CI 0.84–1.82). Between-study heterogeneity was mild for each
analysis (I2 = 0% for COC, I2 = 47% for DMPA, and I2 = 41% for NET-EN). Results from the
two-stage fixed effects and the one-stage meta-analysis models were very similar to those of the
two-stage random effects model (S2 Table).
In multivariable models that included specific covariates for each study, we found associa-
tions with HIV acquisition similar to those for the primary model that controlled for the same
covariates in all studies: the aHR for COC use was 1.07 (95% CI 0.91–1.25), for DMPA use was
1.52 (95% CI 1.27–1.82), and for NET-EN use was 1.27 (95% CI 0.99–1.61) (S2 Table).
In direct comparisons between the three hormonal methods, we found that DMPA use was
associated with an increased risk of HIV acquisition compared with both COC use (aHR 1.43,
95% CI 1.23–1.67) and NET-EN use (aHR 1.32, 95% CI 1.08–1.61) (Fig. 3). There was also
some evidence of increased risk for NET-EN use compared with COC use (aHR 1.30, 95% CI
0.99–1.71, p = 0.055).
Interactions between Hormonal Contraception and Age and HSV-2
Status
We found no statistical evidence for an interaction between age or HSV-2 infection status and
HC on HIV acquisition (Table 4).
Sensitivity Analyses
We found stronger associations between hormonal contraceptive use and HIV acquisition in
the group of studies at higher risk of bias than in those at lower risk of bias (Table 4). Statistical
evidence of interaction was stronger for DMPA use (pinteraction = 0.002) and NET-EN use (pin-
teraction = 0.005) than for COC use (pinteraction = 0.133). In the group of studies at lower risk of
bias, the aHR compared to no HC use was 0.91 (95% CI 0.73–1.14) for COC use, 1.22 (95% CI
0.99–1.50) for DMPA use, and 0.67 (95% CI 0.47–0.96) for NET-EN use. In post hoc analyses
of individual items associated with risk of bias, there was evidence of stronger associations in
studies with lower retention rates (<80%) than in studies with higher retention rates (80%)
for DMPA use (pinteraction = 0.094) and NET-EN use (pinteraction = 0.035) but not for COC use
(pinteraction = 0.235), and in studies missing important confounding variables for NET-EN use
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Fig 2. Multivariable associations between hormonal contraceptive use and HIV acquisition by study,
with non-hormonal-contraceptive group as the reference. (A) aHRs for COC use versus no HC use—
primary model. (B) aHRs for DMPA use versus no HC—primary model. (C) aHRs for NET-EN use versus no
HC—primary model. Individual study results from Cox regression modeling. Pooled aHRs from random
effects meta-analysis adjusted for age, married/living with partner, number of sex partners, condom use, and
region (east Africa, southern Africa, and South Africa). Each horizontal line represents the 95% confidence
interval around the HR. Shaded areas represent the comparative weight of each study. No estimate was
possible if there were not events in the specified contraceptive group. NA, not applicable.
doi:10.1371/journal.pmed.1001778.g002
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Fig 3. Multivariable associations directly comparing different hormonal contraceptives and HIV acquisition by study. (A) aHRs for DMPA versus
COC use—primary model. (B) aHRs for NET-EN versus COC use—primary model. (C) aHRs for DMPA versus NET-EN use—primary model. Individual
study results from Cox regression modeling. Pooled aHRs from random effects meta-analysis adjusted for age, married/living with partner, number of sex
partners, condom use, and region (east Africa, southern Africa, and South Africa). Each horizontal line represents the 95% confidence interval around the
HR. Shaded areas represent the comparative weight of each study. No estimate was possible if there were not events in the specified contraceptive group.
doi:10.1371/journal.pmed.1001778.g003
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(pinteraction = 0.015) but not in studies missing important confounding variables for DMPA use
(pinteraction = 0.225) or COC use (pinteraction = 0.502) (S2 Table). Only one study had an interval
between hormonal contraceptive measurements of>3 mo. There was no statistical evidence of
an interaction between HC and a study having less than 10% of its sample in the no-HC group.
Sensitivity analyses where we censored visits at the time a woman became pregnant, and an
analysis where women who ever became pregnant during the study were excluded, resulted in
estimates of effects for each of the contraceptive methods that were very similar to the primary
study results (S2 Table).
We found stronger associations between hormonal contraceptive use and HIV acquisition in
east Africa than in southern Africa or South Africa for COC use (pinteraction = 0.004) and DMPA
use (pinteraction< 0.001). Interactions between region of study and NET-ENwere not meaningful
because NET-EN was used primarily in South Africa (Table 4). There was increased risk associ-
ated with DMPA use for east Africa and South Africa but not for southern Africa, and an in-
creased risk for COC use in east Africa but not in South Africa or Southern Africa.
We found no statistical evidence for modification of the association between HC and HIV
acquisition according to the background HIV incidence of the component studies. Prespecified
sensitivity analyses using different methods for censoring person-time prior to contraceptive
method switch, limiting studies to only those where the type of injectable was specified, or lim-
iting person-time to periods with no condom use yielded results very similar to the primary
study results (Table 4). In post hoc analyses, we found some evidence for stronger associations
between COC (pinteraction = 0.025) and DMPA (pinteraction = 0.088) use and HIV acquisition in
women reporting transactional sex than among women not reporting transactional sex
(Table 4). We found no important differences between analyses of HC and HIV acquisition
based on type of study design (RCT or cohort study) or after including the published results
from the one study for which we could not obtain individual-level data [61] (S2 Table).
Discussion
In this large IPD meta-analysis, we found that women who use DMPA had an increased risk of
HIV acquisition compared to women not using HC, after controlling for potential confounding
variables. The incidence of HIV was also increased for women using NET-EN, but confidence
intervals were wide, and the increase was not statistically significant after controlling for poten-
tial confounding factors. There was no increased HIV risk associated with COC use. However,
the assessed risk of methodological bias of component studies modified the effect of the hor-
monal contraceptive methods on HIV acquisition, with lower HRs for all contraceptive meth-
ods in studies at lower risk of bias. Direct comparisons between the three contraceptives
suggest that use of DMPA is associated with an increased risk of HIV acquisition compared to
either COC or NET-EN use and that NET-EN use is associated with a borderline increase in
HIV acquisition risk compared to women using COCs (p = 0.055). Neither age nor baseline
HSV-2 infection status modified the effect of the hormonal contraceptive methods on HIV ac-
quisition. The findings from other sensitivity analyses support the overall study findings.
Our finding that oral contraceptive use is not associated with increased risk of HIV, com-
pared with no hormonal contraceptive use, is consistent with descriptive reviews of the findings
from most previous prospective studies [3, 4]. Overall, we found a 50% higher risk of HIV ac-
quisition in women using DMPA, but the increase was reduced to 22% in studies at lower
methodological risk of bias, with confidence intervals including the possibility of no increased
risk. Our meta-analysis results concerning DMPA agree with the findings of an increased HIV
risk in some studies [17, 31, 35, 50, 51, 63], but do not agree with the findings of other studies
[15, 16, 18, 52–56]. Our meta-analysis is, to our knowledge, the largest analysis to date of the
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association between NET-EN and HIV acquisition. Our findings indicate no overall increased
HIV risk associated with NET-EN use; in studies at lower risk of bias, the risk of HIV was even
lower. This is in agreement with five prospective studies in NET-EN users [15, 18–20, 57]. Our
finding of an increased risk of HIV acquisition associated with DMPA use when directly com-
pared with NET-EN use agrees closely with a secondary analysis of data from the VOICE (Vag-
inal and Oral Interventions to Control the Epidemic) microbicide trial (DMPA versus NET-
EN aHR 1.44, 95% CI 1.05–1.98; Table 2) [62], which ended after data collection in our study
was completed.
The quantitative results from this IPD meta-analysis provide several advances over previous
reviews of HC and HIV [1, 3, 4]. First, we provide pooled summaries of associations between
injectable progestin-only contraceptives and HIV acquisition. Second, the individual-level data
allowed a consistent approach to coding and multivariable analysis [14, 64], which overcame
some of the heterogeneity that precluded meta-analysis of the aggregated data [3, 4]. Third,
with data from about 37,000 women and more than 1,800 incident HIV outcomes, we had suf-
ficient statistical power to examine associations between specific contraceptives and HIV risk
and to investigate effect modification in prespecified subgroup analyses. In particular, we
found that methodological features of study design or conduct affected the association between
hormonal contraceptive use and HIV acquisition. Assessing the risk of bias in observational
studies is inherently subjective, so we tried to minimize the subjectivity of these ratings by hav-
ing independent evaluations by two evaluators. We developed our own assessment tool a priori
and included items from published checklists together with items related to other methodologi-
cal features we believed to be important for studies of HC and HIV risk. Other evaluators have
chosen different criteria [3, 4].
It is biologically plausible that DMPA might be more strongly associated with an increased
risk of HIV acquisition than either NET-EN or COCs. Two particular characteristics of DMPA
are worth noting. First, DMPA results in a more hypoestrogenic environment than NET-EN
and estrogen-containing COCs [65, 66], and lack of estrogen has been linked to increased HIV
risk through decreased integrity of the vaginal epithelium and changes to the genital immune
environment [10, 67]. Second, medroxyprogesterone acetate has a higher affinity for binding
with the glucocorticoid receptor than either norethindrone or levonorgestrel (progestins used
in NET-EN and most COCs in this study), and activation of the glucocorticoid receptor has
been linked to suppressed local immunity in several studies [68–70]. Other factors associated
with hormonal contraceptive use might also increase the risk of HIV acquisition, such as
changes in the genital epithelium (e.g., cervical ectopy), changes in the vaginal microbiome
[71–73], changes in the genital immune environment [74–76], and direct effects on HIV (i.e.,
up-regulation of viral replication) [1, 10, 70, 75].
Our meta-analysis has some limitations. First, our collection of datasets might not be repre-
sentative of all datasets that could be used to address the associations between HC and HIV.
This problem affects reviews of observational epidemiology in general because many studies
are secondary analyses of existing datasets; in other studies, the associations of interest may not
have been analyzed or published. Systematic searches of electronic databases will only identify
the published studies. Our search strategy identified both published studies and datasets with
the relevant variables that had not yet been analyzed. The 18 datasets in our meta-analysis in-
cluded the three studies specifically designed to investigate the research question [30, 32, 57],
most of the studies included in a systematic review [3, 4], and ten new datasets [5, 6, 16, 19, 33–
35, 37, 38, 49]. Reasons for excluding studies were independent of the study findings. Our find-
ings did not change with the addition of the one eligible study with HC—HIV results from
among the datasets we were not able to obtain [61] (S2 Table). Second, while IPD meta-analysis
overcomes some of the problems associated with aggregated data, it cannot eliminate bias
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stemming from study design or conduct. In particular, not all component studies had compa-
rable data on all subgroups and potential confounding variables. We worked directly with the
primary investigators from all included studies to try to define variables consistently, but resid-
ual confounding could still be present in our effect estimates. Third, the studies in the meta-
analysis used self-reported measures of sexual behavior, including condom use, which might
not be accurate. If over-reporting of condom use is primarily in the HC groups (compared to
the no-HC group), then the effect of this misreporting would likely be to overinflate the effect
estimates for HC. Conversely, if over-reporting of condom use is greater in the no-HC group
than in the HC groups (as we believe is more likely, given the higher self-reported condom use
in the no-HC group than in the HC groups), then such over-reporting will result in an underes-
timate of the true effect of hormonal contraceptives on HIV acquisition. In any case, we includ-
ed a sensitivity analysis where person-time was limited to those periods when women reported
no condom use, and there was little change in the effect measures for any of the hormonal con-
traceptives. The reports of no condom use are thought to be of higher validity, as there is little
social pressure to underreport condom use in these studies. Fourth, there was evidence of be-
tween-study heterogeneity in the main analyses for NET-EN and DMPA, albeit mild. The I2
values for DMPA (I2 = 47%) and NET-EN (I2 = 41%) were similar, but the patterns of results
differed. In the forest plot of NET-EN and HIV, there was one statistically influential study
with an effect estimate in the opposite direction from the other studies (Fig. 2C, study #12). We
evaluated this pattern and found that this study was not statistically an outlier [77]. Finally,
marginal structural Cox survival models using stabilized inverse probability treatment weight-
ing might have been a more appropriate approach to control time-dependent confounding
than Cox proportional hazards models [3, 78, 79]. However, we could not apply this method
consistently across the different studies.
This IPD meta-analysis found no evidence that COC or NET-EN use increases women’s
risk of HIV compared to women not using HC, and adds to the evidence that DMPAmight in-
crease the risk of HIV acquisition, although some of the excess risk attributed to injectable con-
traception results from methodological limitations of the studies, including poor follow-up and
residual confounding. Because of the importance of effective family planning to women’s re-
productive health and to the morbidity and mortality of women and children, it is critical to
obtain the highest quality evidence possible to inform the decisions of women, clinicians, and
policy-makers in regions or risk groups with high HIV incidence. The results of this study also
provide important information to inform the design of an RCT [80, 81], which would provide
more direct evidence of the effects of different hormonal contraceptive methods, in particular
DMPA, on the risk of HIV acquisition. In the absence of definitive data, however, women with
high HIV risk need access to additional safe and effective contraceptive options, and they need
to be counseled about the relative risks and benefits of the available family planning methods.
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Editors’ Summary
Background
AIDS has killed about 36 million people since the first recorded case of the disease in 1981.
About 35 million people (including 25 million living in sub-Saharan Africa) are currently
infected with HIV, the virus that causes AIDS, and every year, another 2.3 million people
become newly infected with HIV. At the beginning of the epidemic, more men than
women were infected with HIV. Now, about half of all adults infected with HIV are
women. In 2013, almost 60% of all new HIV infections among young people aged 15–24
years occurred among women, and it is estimated that, worldwide, 50 young women are
newly infected with HIV every hour. Most women become infected with HIV through un-
protected intercourse with an infected male partner—biologically, women are twice as
likely to become infected through unprotected intercourse as men. A woman’s risk of be-
coming infected with HIV can be reduced by abstaining from sex, by having one or a few
partners, and by always using condoms.
WhyWas This Study Done?
Women and societies both benefit from effective contraception. When contraception is
available, women can avoid unintended pregnancies, fewer women and babies die during
pregnancy and childbirth, and maternal and infant health improves. However, some (but
not all) observational studies (investigations that measure associations between the charac-
teristics of participants and their subsequent development of specific diseases) have re-
ported an association between hormonal contraceptive use and an increased risk of HIV
acquisition by women. So, does hormonal contraception increase the risk of HIV acquisi-
tion among women or not? Here, to investigate this question, the researchers undertake an
individual participant data meta-analysis of studies conducted in sub-Saharan Africa (a re-
gion where both HIV infection and unintended pregnancies are common) to compare the
incidence of HIV infection (the number of new cases in a population during a given time
period) among women using and not using hormonal contraception. Meta-analysis is a
statistical method that combines the results of several studies; an individual participant
data meta-analysis combines the data recorded for each individual involved in the studies
rather than the aggregated results from each study.
What Did the Researchers Do and Find?
The researchers included 18 studies that measured hormonal contraceptive use and inci-
dent HIV infection among women aged 15–49 years living in sub-Saharan Africa in their
meta-analysis. More than 37,000 women took part in these studies, and 1,830 became
newly infected with HIV. Half of the women were not using hormonal contraception, a
quarter were using depot-medroxyprogesterone acetate (DMPA; an injectable hormonal
contraceptive), and the remainder were using combined oral contraceptives (COCs) or
norethisterone enanthate (NET-EN, another injectable contraceptive). After adjustment
for other factors likely to influence HIV acquisition (for example, condom use), women
using DMPA had a 1.5-fold increased risk of HIV acquisition compared to women not
using hormonal contraception. There was a slightly increased risk of HIV acquisition
among women using NET-EN compared to women not using hormonal contraception,
but this increase was not statistically significant (it may have happened by chance alone).
There was no increased risk of HIV acquisition associated with COC use. DMPA use was
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associated with a 1.43-fold and 1.32-fold increased risk of HIV acquisition compared with
COC and NET-EN use, respectively. Finally, neither age nor herpes simplex virus 2 infec-
tion status modified the effect of hormonal contraceptive use on HIV acquisition.
What Do These Findings Mean?
The findings of this individual patient data meta-analysis provide no evidence that COC
or NET-EN use increases a woman’s risk of acquiring HIV, but add to the evidence sug-
gesting that DMPA use increases the risk of HIV acquisition. These findings are likely to
be more accurate than those of previous meta-analyses that used aggregated data but are
likely to be limited by the quality, design, and representativeness of the studies included in
the analysis. These findings nevertheless highlight the need to develop additional safe and
effective contraceptive options for women at risk of HIV, particularly those living in sub-
Saharan Africa, where although contraceptive use is generally low, DMPA is the most
widely used hormonal contraceptive. In addition, these findings highlight the need to initi-
ate randomized controlled trials to provide more definitive evidence of the effects of hor-
monal contraception, particularly DMPA, on HIV risk.
Additional Information.
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001778.
• Information is available from the US National Institute of Allergy and Infectious Dis-
eases on HIV infection and AIDS
• NAM/aidsmap provides basic information about HIV/AIDS, and summaries of recent
research findings on HIV care and treatment, including personal stories about living
with HIV/AIDS and a news report on this meta-analysis
• Information is available from Avert, an international AIDS charity, on many aspects of
HIV/AIDS, including detailed information on women, HIV, and AIDS, and on HIV and
AIDS in South Africa (in English and Spanish); personal stories of women living with
HIV are available
• TheWorld Health Organization provides information on all aspects of HIV/AIDS (in
several languages); information about a 2012 WHO technical consultation about
hormonal contraception and HIV
• The 2013 UNAIDSWorld AIDS Day report provides up-to-date information about the
AIDS epidemic and efforts to halt it; UNAIDS also provides information about HIV and
hormonal contraception
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